Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy

Science

Volumn 354, Issue 6309, 2016, Pages 197-202

  Byrareddy, Siddappa N ^a,j   Arthos, James ^b   Cicala, Claudia ^b   Villinger, Francois ^a,c,k   Ortiz, Kristina T ^a   Little, Dawn ^a   Sidell, Neil ^a   Kane, Maureen A ^d   Yu, Jianshi ^d   Jones, Jace W ^d   Santangelo, Philip J ^e   Zurla, Chiara ^e   McKinnon, Lyle R ^f,l   Arnold, Kelly B ^g   Woody, Caroline E ^g   Walter, Lutz ^h   Roos, Christian ^h   Noll, Angela ^h   Van Ryk, Donald ^b   Jelicic, Katija ^b   Cimbro, Raffaello ⁱ   Gumber, Sanjeev ^c   Reid, Michelle D ^a   Adsay, Volkan ^a   Amancha, Praveen K ^c   Mayne, Ann E ^a   Parslow, Tristram G ^a   Fauci, Anthony S ^b   Ansari, Aftab A ^a   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^e Emory University   (United States)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g UNIVERSITY OF MICHIGAN   (United States)

^h GERMAN PRIMATE CENTER   (Germany)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k UNIVERSITY OF LOUISIANA AT LAFAYETTE   (United States)

^l UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA4BETA7 INTEGRIN; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD163 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; D DIMER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 120; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2A; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ALPHA4 INTEGRIN; BETA INTEGRIN; BETA7 INTEGRIN; CYTOKINE; GP120 PROTEIN, SIMIAN IMMUNODEFICIENCY VIRUS; MEMBRANE PROTEIN; VEDOLIZUMAB; VIRUS ENVELOPE PROTEIN;

ANTIBODY; CHEMOTHERAPY; DRUG; ELECTRONIC EQUIPMENT; IMMUNE SYSTEM; INFECTIVITY; PRIMATE; VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GASTROINTESTINAL TRACT; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TH17 CELL; TH22 CELL; VIREMIA; VIRUS LOAD; ANIMAL; BLOOD; CD4+ T LYMPHOCYTE; DISEASE MODEL; FEMALE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MALE; MULTIMODALITY CANCER THERAPY; PASSIVE IMMUNIZATION; PROCEDURES; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

ANIMALIA; MACACA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL TRACT; IMMUNIZATION, PASSIVE; INFUSIONS, INTRAVENOUS; INTEGRIN ALPHA4; INTEGRIN BETA CHAINS; KILLER CELLS, NATURAL; MACACA MULATTA; MALE; MEMBRANE GLYCOPROTEINS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTE SUBSETS; TRETINOIN; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIREMIA;

EID: 84991712477     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aag1276     Document Type: Article

References (35)

1. J. Saison, L. Cotte, C. Chidiac, T. Ferry, BMJ Case Rep. 2012 (mar08 1), bcr1020114905 (2012).
2. A. H. Warriner, G. A. Burkholder, E. T. Overton, Infect. Dis. Clin. North Am. 28, 457-476 (2014).
3. L. Barrett, K. R. Fowke, M. D. Grant, AIDS Rev. 14,159-167 (2012).
4. R. S. Veazey et al., Science 280, 427-431 (1998).
5. J. Ananworanich, K. Dubé, N. Chomont, Curr. Opin. HIV AIDS 10, 18-28 (2015).
6. M. Briskin et al., Am. J. Pathol. 151, 97-110 (1997).
7. D. J. Erle et al., J. Immunol. 153, 517-528 (1994).
8. M. Kader et al., Mucosal Immunol. 2, 439-449 (2009).
9. X. Wang et al., Mucosal Immunol. 2, 518-526 (2009).
10. C. Cicala et al., Proc. Natl. Acad. Sci. U.S.A. 106, 20877-20882 (2009).
11. X. Lu et al., Cell. Mol. Immunol. 10.1038/cmi.2015.60 (2015).
12. E. Martinelliet al., J. Acquir. Immune Defic. Syndr. 64, 325-331 (2013).
13. S. N. Byrareddy et al., Nat. Med. 20, 1397-1400 (2014).
14. M. Guadalupe et al., J. Virol. 77, 11708-11717 (2003).
15. J. M. Brenchley, D. C. Douek, Mucosal Immunol. 1, 23-30 (2008).
16. Q. Li et al., Nature 434, 1148-1152 (2005).
17. J. J. Mattapallil et al., Nature 434, 1093-1097 (2005).
18. S. Mehandru et al., J. Virol. 81, 599-612 (2007).
19. H. Xu, X. Wang, R. S. Veazey, J. AIDS Clin. Res. 5, 302 (2014).
20. P. J. Santangelo et al., Nat. Methods 12, 427-432 (2015).
21. H. N. Kløverpris et al., Immunity 44, 391-405 (2016).
22. M. Vaccari et al., Nat. Med. 22, 762-770 (2016).
23. M. Iwata et al., Immunity 21, 527-538 (2004).
24. A. C. Ross, Am. J. Clin. Nutr. 96, 1166S-1172S (2012).
25. W. Agace, Immunol. Lett. 128, 21-23 (2010).
26. S. Sirisinha, Asian Pac. J. Allergy Immunol. 33, 71-89 (2015).
27. R. Zeng et al., Mucosal Immunol. 6, 847-856 (2013).
28. R. Gottardo et al., PLOS ONE 8, e75665 (2013).
29. P. Pegu et al., J. Virol. 87, 1708-1719 (2013).
30. M. Rolland et al., Nature 490, 417-420 (2012).
31. Y. Guo, C. Brown, C. Ortiz, R. J. Noelle, Physiol. Rev. 95, 125-148 (2015).
32. J. A. Hall, J. R. Grainger, S. P. Spencer, Y. Belkaid, Immunity 35, 13-22 (2011).
33. R. Xiao et al., J. Dermatol. 38, 345-353 (2011).
34. M. Jovani, S. Danese, Curr. Drug Targets 14, 1433-1443 (2013).
35. Vedolizumab, FDA Advisory Committee Recommends Approval of Vedolizumab (Drugs.com, 2013); www.drugs.com/nda/vedolizumab-131209.html.